Literature DB >> 26869421

Correlating the Impact of Well-Defined Oligosaccharide Structures on Physical Stability Profiles of IgG1-Fc Glycoforms.

Apurva S More1, Vishal M Toprani1, Solomon Z Okbazghi2, Jae H Kim1, Sangeeta B Joshi1, C Russell Middaugh1, Thomas J Tolbert2, David B Volkin3.   

Abstract

As part of a series of articles in this special issue describing 4 well-defined IgG1-Fc glycoforms as a model system for biosimilarity analysis (high mannose-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc aglycosylated), the focus of this work is comparisons of their physical properties. A trend of decreasing apparent solubility (thermodynamic activity) by polyethylene glycol precipitation (pH 4.5, 6.0) and lower conformational stability by differential scanning calorimetry (pH 4.5) was observed with reducing size of the N297-linked oligosaccharide structures. Using multiple high-throughput biophysical techniques, the physical stability of the Fc glycoproteins was then measured in 2 formulations (NaCl and sucrose) across a wide range of temperatures (10°C-90°C) and pH (4.0-7.5) conditions. The data sets were used to construct 3-index empirical phase diagrams and radar charts to visualize the regions of protein structural stability. Each glycoform showed improved stability in the sucrose (vs. salt) formulation. The HM-Fc and Man5-Fc displayed the highest relative stability, followed by GlcNAc-Fc, with N297Q-Fc being the least stable. Thus, the overall physical stability profiles of the 4 IgG1-Fc glycoforms also show a correlation with oligosaccharide structure. These data sets are used to develop a mathematical model for biosimilarity analysis (as described in a companion article by Kim et al. in this issue).
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fc; IgG; conformation; formulation; glycosylation; monoclonal antibody; spectroscopy; stability

Mesh:

Substances:

Year:  2015        PMID: 26869421     DOI: 10.1016/j.xphs.2015.10.014

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.

Authors:  Solomon Z Okbazghi; Apurva S More; Derek R White; Shaofeng Duan; Ishan S Shah; Sangeeta B Joshi; C Russell Middaugh; David B Volkin; Thomas J Tolbert
Journal:  J Pharm Sci       Date:  2016-01-09       Impact factor: 3.534

2.  Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms.

Authors:  Olivier Mozziconacci; Solomon Okbazghi; Apurva S More; David B Volkin; Thomas Tolbert; Christian Schöneich
Journal:  J Pharm Sci       Date:  2016-01-11       Impact factor: 3.534

3.  The Botanical Drug Substance Crofelemer as a Model System for Comparative Characterization of Complex Mixture Drugs.

Authors:  Peter A Kleindl; Jian Xiong; Asha Hewarathna; Olivier Mozziconacci; Maulik K Nariya; Adam C Fisher; Eric J Deeds; Sangeeta B Joshi; C Russell Middaugh; Christian Schöneich; David B Volkin; M Laird Forrest
Journal:  J Pharm Sci       Date:  2017-07-22       Impact factor: 3.534

4.  Impact of Glycosylation on the Local Backbone Flexibility of Well-Defined IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry.

Authors:  Apurva S More; Ronald T Toth; Solomon Z Okbazghi; C Russell Middaugh; Sangeeta B Joshi; Thomas J Tolbert; David B Volkin; David D Weis
Journal:  J Pharm Sci       Date:  2018-05-08       Impact factor: 3.534

5.  Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant.

Authors:  Vishal M Toprani; John M Hickey; Neha Sahni; Ronald T Toth; George A Robertson; C Russell Middaugh; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2017-08-02       Impact factor: 3.534

6.  Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration.

Authors:  Yue Hu; Ozan S Kumru; Jian Xiong; Lorena R Antunez; John Hickey; Yang Wang; Lisa Cavacini; Mark Klempner; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2019-07-29       Impact factor: 3.534

7.  Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.

Authors:  Sanjeev Agarwal; John M Hickey; Neha Sahni; Ronald T Toth; George A Robertson; Robert Sitrin; Stanley Cryz; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2019-08-07       Impact factor: 3.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.